Compare STOK & ALG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | ALG |
|---|---|---|
| Founded | 2014 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2019 | 1996 |
| Metric | STOK | ALG |
|---|---|---|
| Price | $24.97 | $145.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | $46.46 | ★ $204.80 |
| AVG Volume (30 Days) | ★ 782.2K | 133.9K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | ★ 92.73 | N/A |
| EPS | N/A | ★ 4.96 |
| Revenue | $184,420,000.00 | ★ $1,603,715,000.00 |
| Revenue This Year | N/A | $6.51 |
| Revenue Next Year | $39.98 | $4.10 |
| P/E Ratio | ★ N/A | $29.59 |
| Revenue Growth | ★ 404.50 | N/A |
| 52 Week Low | $20.32 | $145.76 |
| 52 Week High | $40.22 | $219.88 |
| Indicator | STOK | ALG |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 27.83 |
| Support Level | $24.21 | N/A |
| Resistance Level | $33.61 | $173.93 |
| Average True Range (ATR) | 1.33 | 3.85 |
| MACD | 0.35 | -0.66 |
| Stochastic Oscillator | 56.19 | 7.58 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.